Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RAPT vs ORKA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ORKA Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 3–3 Matrix Metrics)

ORKA Overall Winner 6-Pillar Tally: RAPT 0 – 4 ORKA (2 Tie) Matrix Metrics: RAPT 3 – 3 ORKA

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas ORKA carries 43.3/100 (HOLD) at $99.83 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. ORKA 43.3/100 HOLD), ORKA captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPT vs ORKA
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67
ORKA NASDAQ Head-to-Head Winner
Oruka Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.83
-5.23% 1D
Market Cap $7.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 68% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 24.0 Fund 40.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.1 · SMA20: $96.12 · SMA50: $89.82

6-Pillar Scorecard Institutional Category Breakdown (RAPT 0 – 4 ORKA)

Columns: Metric · RAPT · ORKA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ORKA
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $1.7B $7.1B
3. Profitability & Quality ORKA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -85.4% -18.1%
4. Balance Sheet & Cash Flow ORKA
Cash Generation (TTM) N/A -$124M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.02 Book/Sh · -85.4% ROE $189M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ORKA
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 0.8% (<1st %ile) 78.7% (19th %ile)
Put/Call OI Skew N/A 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPT (3) vs ORKA (3)
Institutional Metric RAPT ORKA Criterion Row Edge
Market Capitalization
Scale
$1.7B $7.1B Larger Scale ORKA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth ORKA
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-85.4% -18.1% Higher ROE ORKA
52-Week Range Position
Momentum
100% ($1–$58) 83% ($25–$116) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
-0.02β · 2% Vol 1.35β · 68% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.02 Book/Sh · -85.4% ROE) -$124M ($189M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +5.13 pp
RAPT: +0.68% · ORKA: -4.45%
3M Horizon RAPT +63.84 pp
RAPT: +74.44% · ORKA: +10.6%
6M Horizon RAPT +77.54 pp
RAPT: +101.95% · ORKA: +24.41%
1Y Horizon RAPT +77.54 pp
RAPT: +101.95% · ORKA: +24.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs ORKA. Trailing 12-month operating profitability (RAPT 0.0% vs ORKA 0.0%) and valuation multiples (RAPT N/M vs ORKA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M
ORKA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-18.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ORKA BREAKOUT
141d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 19th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ORKA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ORKA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RAPT vs ORKA Key Questions & Quantitative Answers

As of Nov 16, 2026, Oruka Therapeutics, Inc. (ORKA) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas ORKA carries 43.3/100 (HOLD) at $99.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. ORKA 43.3/100 HOLD), ORKA captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).

ORKA leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ORKA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus N/A for ORKA. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ORKA.

RAPT and ORKA trade at balanced relative valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ORKA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus ORKA (-18.1% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, ORKA carries 78.7% implied volatility (19th %ile, Compressed (<25th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.35β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.